Ahmedabad, August 7, 2025 Lincoln Pharmaceuticals Ltd., a leading name in India’s pharmaceutical export sector, has reappointed Mahendra G. Patel as Managing Director, reinforcing its commitment to stable leadership and strategic continuity. The announcement comes alongside the company’s robust financial results for the June 2025 quarter, with consolidated net profit rising to ₹276.8 million and revenue from operations reaching ₹1.54 billion.
This dual development marks a significant moment for Lincoln Pharma, which continues to thrive under Patel’s seasoned guidance and a business model focused on affordable healthcare and global expansion.
Financial Performance: June Quarter 2025
Lincoln Pharmaceuticals delivered a strong set of numbers for Q1 FY26, reflecting operational efficiency and market resilience. The company’s consolidated revenue from operations stood at ₹1.54 billion, up from ₹1.36 billion in the same quarter last year. Net profit surged to ₹276.8 million, a 45.6% increase year-on-year, driven by improved margins and export growth.
The EBITDA for the quarter was ₹267.18 million, marking a 43.49% rise compared to the previous year. Despite inflationary pressures and rising input costs, Lincoln maintained a healthy net profit margin of 6.88%, showcasing its ability to manage costs effectively while scaling operations.
Leadership Reaffirmed: Mahendra G. Patel’s Continued Tenure
Mahendra G. Patel, one of the founding members of Lincoln Pharmaceuticals, has been reappointed as Managing Director. His leadership has been pivotal in transforming Lincoln from a domestic player into a global pharmaceutical exporter with a presence in over 60 countries.
Patel’s tenure has been marked by:
Strategic expansion into Africa, Southeast Asia, and Latin America
Establishment of WHO-GMP and EU-GMP certified manufacturing facilities
Investment in R&D for formulation development and innovation
A focus on cost-effective therapeutic solutions across multiple dosage forms
His reappointment signals investor confidence and a continued focus on long-term growth, innovation, and operational excellence.
Strategic Growth and Market Position
Lincoln Pharmaceuticals has built a reputation for quality and affordability. Its product portfolio includes over 300 formulations, ranging from tablets and capsules to injectables and ointments. The company’s manufacturing units in Ahmedabad and Mehsana are ISO 9001:2015 certified and comply with WHO-cGMP standards.
Exports contribute nearly 30% of Lincoln’s total revenue, and the company is actively expanding its footprint in regulated markets. A new API manufacturing facility is currently undergoing trial runs and is expected to begin commercial production within the next two years, further enhancing Lincoln’s vertical integration and cost control.
Market Sentiment and Stock Performance
Lincoln Pharmaceuticals’ stock (NSE: LINP) is currently trading around ₹534, with a market capitalization of approximately ₹10.76 billion. Despite short-term volatility, the stock has delivered a 177.82% return over the past five years, outperforming many of its mid-cap pharma peers.
The company maintains a low debt profile and strong cash flows, making it attractive to long-term investors. Its P/E ratio stands at 13.02, and the dividend yield is approximately 0.33%, reflecting a balanced approach to shareholder returns and reinvestment.
Outlook and Investor Expectations
With Mahendra G. Patel continuing at the helm and a strong Q1 performance, Lincoln Pharmaceuticals is well-positioned for sustained growth. The company’s strategic priorities include:
Commercial launch of the new API facility
Expansion into new geographies and therapeutic segments
Continued investment in R&D and regulatory compliance
Enhancing operational efficiency and margin improvement
Investors will be closely watching for updates on facility approvals, product launches, and export performance in the coming quarters.
Sources: Lincoln Pharmaceuticals Ltd – Official Website, Business Standard, Moneycontrol, Investing.com, Google Finance
